Reduce memory impairment using levetiracetam
- Trial ID
- NCT04643327
- Official Title
- Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study
- Goal
- Reduce memory impairment using levetiracetam
- Phase
- PHASE2
- Status
- RECRUITING
- Sponsor
- The University of Queensland
- Study Type
- INTERVENTIONAL
- Enrollment
- 28 participants
- Conditions
- Parkinson Disease, Mild Cognitive Impairment, Memory Impairment
- Interventions
- Levetiracetam, Placebo
Plain-Language Summary
Trying to see whether low-dose levetiracetam can reduce abnormal hippocampal activity and improve memory in people with Parkinson's who have amnestic mild cognitive impairment. Levetiracetam is an anticonvulsant that binds the synaptic vesicle protein SV2A to calm excess neuronal firing and normalize memory encoding, it does not act on dopamine pathways and is not expected to change levodopa metabolism, though it can cause mood or behavioral side effects and should not be used with other anticonvulsants. The trial is a double-blind, randomized within-subject crossover versus placebo with MRI assessments. They want people with Parkinson's with or without memory impairment plus healthy volunteers who can have MRI, and they exclude anyone with dementia, major psychiatric illness, current anticonvulsant use, severe renal impairment, or females of childbearing potential.
Locations
- University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Levetiracetam. Trying to see whether low-dose levetiracetam can reduce abnormal hippocampal activity and improve memory in people with Parkinson's who have amnestic mild cognitive impairment. Levetiracetam is an anticonvulsant that binds the synaptic vesicle protein SV2A to calm excess neuronal firing and normalize memory encoding, it does not act on dopamine pathways and is not expected to change levodopa metabolism, though it can cause mood or behavioral side effects and should not be used with other anticonvulsants. The trial is a double-blind, randomized within-subject crossover versus placebo with MRI assessments. They want people with Parkinson's with or without memory impairment plus healthy volunteers who can have MRI, and they exclude anyone with dementia, major psychiatric illness, current anticonvulsant use, severe renal impairment, or females of childbearing potential.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 2 trial is estimated to last approximately 3 years and 11 months.